New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - aspirin 100mg (2 x 50mg);  ; atorvastatin calcium trihydrate 21.69mg (2 x 10.845mg (equivalent to 20mg atorvastatin));  ; ramipril 10mg;   - combination capsule - 100mg/20mg/10mg - active: aspirin 100mg (2 x 50mg)   excipient: microcrystalline cellulose opadry white oy-b-28920 amb purified talc sodium starch glycolate active: atorvastatin calcium trihydrate 21.69mg (2 x 10.845mg (equivalent to 20mg atorvastatin))   excipient: calcium carbonate colloidal silicon dioxide crospovidone hyprolose lactose monohydrate magnesium stearate opadry green 06o21881 polysorbate 80 pregelatinised maize starch active: ramipril 10mg   excipient: hypromellose microcrystalline cellulose opadry yellow sodium stearyl fumarate starch black ink (trinomia) gelatin iron oxide red titanium dioxide - trinomia is indicated for the secondary prevention of cardiovascular accidents as substitution therapy in adult patients adequately controlled with the mono-components given concomitantly at equivalent therapeutical doses

New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - aspirin 100mg (2 x 50mg);  ; atorvastatin calcium trihydrate 21.69mg (2 x 10.845mg (equivalent to 20mg atorvastatin));  ; ramipril 2.5mg;   - combination capsule - 100mg/20mg/2.5mg - active: aspirin 100mg (2 x 50mg)   excipient: microcrystalline cellulose opadry white oy-b-28920 amb purified talc sodium starch glycolate active: atorvastatin calcium trihydrate 21.69mg (2 x 10.845mg (equivalent to 20mg atorvastatin))   excipient: calcium carbonate colloidal silicon dioxide crospovidone hyprolose lactose monohydrate magnesium stearate opadry green 06o21881 polysorbate 80 pregelatinised maize starch active: ramipril 2.5mg   excipient: hypromellose microcrystalline cellulose opadry yellow 80w32039 sodium stearyl fumarate starch black ink (trinomia) gelatin iron oxide black titanium dioxide - trinomia is indicated for the secondary prevention of cardiovascular accidents as substitution therapy in adult patients adequately controlled with the mono-components given concomitantly at equivalent therapeutical doses

New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - aspirin 100mg (2 x 50mg);  ; atorvastatin calcium trihydrate 21.69mg (2 x 10.845mg (equivalent to 20mg atorvastatin));  ; ramipril 5mg;   - combination capsule - 100mg/20mg/5mg - active: aspirin 100mg (2 x 50mg)   excipient: microcrystalline cellulose opadry white oy-b-28920 amb purified talc sodium starch glycolate active: atorvastatin calcium trihydrate 21.69mg (2 x 10.845mg (equivalent to 20mg atorvastatin))   excipient: calcium carbonate colloidal silicon dioxide crospovidone hyprolose lactose monohydrate magnesium stearate opadry green 06o21881 polysorbate 80 pregelatinised maize starch active: ramipril 5mg   excipient: hypromellose microcrystalline cellulose opadry yellow sodium stearyl fumarate starch black ink (trinomia) gelatin iron oxide black iron oxide red titanium dioxide - trinomia is indicated for the secondary prevention of cardiovascular accidents as substitution therapy in adult patients adequately controlled with the mono-components given concomitantly at equivalent therapeutical doses

Australia - English - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - cobicistat, quantity: 150 mg - tablet - excipient ingredients: croscarmellose sodium; magnesium stearate; microcrystalline cellulose; titanium dioxide; sunset yellow fcf aluminium lake; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - tybost is indicated as a pharmacokinetic enhancer of appropriate hiv-1 protease inhibitors in adults (see dosage and administration).

United States - English - NLM (National Library of Medicine)

abbvie inc. - lopinavir (unii: 2494g1jf75) (lopinavir - unii:2494g1jf75), ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825) - lopinavir 100 mg - kaletra is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and pediatric patients 14 days and older. limitations of use: - genotypic or phenotypic testing and/or treatment history should guide the use of kaletra. the number of baseline lopinavir resistance-associated substitutions affects the virologic response to kaletra [see microbiology ( 12.4 )] . - kaletra is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., toxic epidermal necrolysis, stevens-johnson syndrome, erythema multiforme, urticaria, angioedema) to any of its ingredients, including ritonavir. - kaletra is contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening reactions [see drug interactions ( 7.1 ) and clinical pharmacology ( 12.3 )] . ○ alpha 1- adrenoreceptor antagonist: alfuzosin ○ antianginal: ranolazine ○ antiar

United States - English - NLM (National Library of Medicine)

dispensing solutions, inc. - lopinavir (unii: 2494g1jf75) (lopinavir - unii:2494g1jf75), ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825) - lopinavir 200 mg - kaletra is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection. the following points should be considered when initiating therapy with kaletra: - the use of other active agents with kaletra is associated with a greater likelihood of treatment response [see clinical pharmacology (12.4) and clinical studies (14)] . - genotypic or phenotypic testing and/or treatment history should guide the use of kaletra [see clinical pharmacology (12.4)] . the number of baseline lopinavir resistance-associated substitutions affects the virologic response to kaletra [see clinical pharmacology (12.4)] . - once daily administration of kaletra is not recommended for any pediatric patients. - kaletra is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., toxic epidermal necrolysis, stevens-johnson syndrome, erythema multiforme) to any of its ingredients, including ritonavir. - co-administration of kaletra is contraindicated with drugs tha

Australia - English - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - tenofovir disoproxil fumarate, quantity: 300 mg; emtricitabine, quantity: 200 mg - tablet, film coated - excipient ingredients: indigo carmine aluminium lake; magnesium stearate; croscarmellose sodium; titanium dioxide; triacetin; pregelatinised maize starch; microcrystalline cellulose; lactose monohydrate; hypromellose - treatment of hiv-1 infection,truvada is indicated for the treatment of hiv infected adults over the age of 18 years, in combination with other antiretroviral agents.,pre-exposure prophylaxis truvada is indicated in combination with safer sex practices for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 in adults at high risk. this indication is based on clinical trials in men who have sex with men (msm) at high risk for hiv-1 infection and in heterosexual serodiscordant couples (see clinical studies).

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - emtricitabine, quantity: 200 mg; efavirenz, quantity: 600 mg; tenofovir disoproxil maleate, quantity: 300 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; sodium metabisulfite; hyprolose; colloidal anhydrous silica; croscarmellose sodium; magnesium stearate; ferric oxide; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - tenofovir disoproxil/ emtricitabine/ efavirenz mylan 300/200/600 is indicated for the treatment of hiv infected adults over the age of 18 years.,this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts in controlled studies of viread, emtriva and stocrin in treatment-na?ve and treatment experienced adults.

United States - English - NLM (National Library of Medicine)

american health packaging - ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825) - ritonavir tablets are indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection. - when co-administering ritonavir tablets with other protease inhibitors, see the full prescribing information for that protease inhibitor including contraindication information. - ritonavir tablets are contraindicated in patients with known hypersensitivity (e.g., toxic epidermal necrolysis (ten) or stevens-johnson syndrome) to ritonavir or any of its ingredients. - ritonavir tablets are contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening reactions [see drug interactions (7.1) and clinical pharmacology (12.3)]. - alpha 1- adrenoreceptor antagonist: alfuzosin - antianginal: ranolazine - antiarrhythmics: amiodarone, dronedarone, flecainide, propafenone, quinidine - antifungal: voriconazole - anti-gout: colchicine - antipsychotics: lurasidone, pimozide - ergot de

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - emtricitabine, quantity: 200 mg; tenofovir disoproxil fumarate, quantity: 300 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; pregelatinised starch; croscarmellose sodium; magnesium stearate; lactose monohydrate; titanium dioxide; hypromellose; triacetin; indigo carmine aluminium lake - treatment of hiv-1 infection: cipla tenofovir + emtricitabine 300/200 is indicated for the treatment of hiv infected adults over the age of 18 years, in combination with other antiretroviral agents. pre-exposure prophylaxis: cipla tenofovir + emtricitabine 300/200 is indicated in combination with safer sex practices for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 in adults at high risk. this indication is based on clinical trials in men who have sex with men (msm) at high risk for hiv-1 infection and in heterosexual serodiscordant couples.